279. Fernandez Juarez G, Luno J, Barrio V, et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial. Am J Kidney Dis. 2013;61:211 218. 280. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892 1903. 281. Sharma P, Blackburn RC, Parke CL, et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Cochrane Database Syst Rev. 2011;10:CD007751. 282. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. 283. Ferrari P, Marti HP, P ster M, et al. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens. 2002;20:125 130. 284. Leon SJ, Tangri N. The use of renin-angiotensin system inhibitors in patients with chronic kidney disease. Can J Cardiol. 2019;35:1220 1227. 285. Anand V, Kshiragar AV, Navaneethan SD, et al. Direct renin inhibitors for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2013;9:CD01072. 286. Bakris GL, Oparil S, Purkayastha D, et al. Randomized study of antihypertensive ef cacy and safety of combination aliskiren/valsartan vs valsartan monotherapy in hypertensive participants with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2013;15:92 100. 287. Fogari R, Mugellini A, Zoppi A, et al. Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria. Expert Opin Pharmacother. 2013;14:371 384. 288. Ohsawa M, Tamura K, Kanaoka T, et al. Addition of aliskiren to angiotensin receptor blocker improves ambulatory blood pressure pro le and cardiorenal function better than addition of benazepril in chronic kidney disease. Int J Mol Sci. 2013;14:15361 15375. 289. 